Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients

Elani Streja, Hsin Yi Wang, Wei Ling Lau, Miklos Z. Molnar, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Jongha Park

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Mineral and bone disorder (MBD) is common and associated with mortality in patients with chronic kidney disease (CKD) Given that disarrays in serum phosphorus (P) and parathyroid hormone (PTH) levels and their changes over time are closely interrelated, modeling mortality-predictability of their combinations may help improve CKD patient management. Methods: A historical cohort study was undertaken to evaluate the joint effect of serum P and PTH levels on mortality in 107,299 chronic hemodialysis (HD) patients. Changes in serum P and PTH levels over 6. months, in particular discordant changes, were also modeled with mortality. Results: HD patients were 64. ±. 15 (mean. ±. SD). years old and included 45% women, 33% African-American, and 59% diabetic. Compared with serum P level ≥. 7.0. mg/dL and PTH level ≥. 600. pg/mL, adjusted hazard ratio (HR) tended to be lowest in patients with serum P level of 3.5 <. 5.5. mg/dL combined with PTH level of 150 <. 300. pg/mL (HR 0.64, 95% confidence interval 0.61-0.67). A change over time in serum P level towards the 3.5 <. 5.5. mg/dL range from higher or lower ranges was associated with a decreased mortality, whereas only change in PTH level from <. 150. pg/mL to 150 <. 300. pg/mL range was associated with a lower risk of mortality. Upon discordant changes of PTH and P, i.e., decrease in one of the two measures while the other increased, no change in mortality risk was observed. Conclusion: In CKD-MBD management, patent survival is the greatest with controlling both serum P and PTH levels in balance. Tailoring an individualized treatment strategy in CKD-MBD may benefit patients. Further studies are needed.

Original languageEnglish (US)
Pages (from-to)201-207
Number of pages7
JournalBone
Volume61
DOIs
StatePublished - Apr 1 2014

Fingerprint

Parathyroid Hormone
Phosphorus
Renal Dialysis
Mortality
Serum
Chronic Kidney Disease-Mineral and Bone Disorder
Chronic Renal Insufficiency
Disease Management
African Americans
Minerals
Cohort Studies
Confidence Intervals
Bone and Bones
Survival

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. / Streja, Elani; Wang, Hsin Yi; Lau, Wei Ling; Molnar, Miklos Z.; Kovesdy, Csaba P.; Kalantar-Zadeh, Kamyar; Park, Jongha.

In: Bone, Vol. 61, 01.04.2014, p. 201-207.

Research output: Contribution to journalArticle

Streja, Elani ; Wang, Hsin Yi ; Lau, Wei Ling ; Molnar, Miklos Z. ; Kovesdy, Csaba P. ; Kalantar-Zadeh, Kamyar ; Park, Jongha. / Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. In: Bone. 2014 ; Vol. 61. pp. 201-207.
@article{6fe5d6787ec64ce7819ec21b4e4d617a,
title = "Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients",
abstract = "Background: Mineral and bone disorder (MBD) is common and associated with mortality in patients with chronic kidney disease (CKD) Given that disarrays in serum phosphorus (P) and parathyroid hormone (PTH) levels and their changes over time are closely interrelated, modeling mortality-predictability of their combinations may help improve CKD patient management. Methods: A historical cohort study was undertaken to evaluate the joint effect of serum P and PTH levels on mortality in 107,299 chronic hemodialysis (HD) patients. Changes in serum P and PTH levels over 6. months, in particular discordant changes, were also modeled with mortality. Results: HD patients were 64. ±. 15 (mean. ±. SD). years old and included 45{\%} women, 33{\%} African-American, and 59{\%} diabetic. Compared with serum P level ≥. 7.0. mg/dL and PTH level ≥. 600. pg/mL, adjusted hazard ratio (HR) tended to be lowest in patients with serum P level of 3.5 <. 5.5. mg/dL combined with PTH level of 150 <. 300. pg/mL (HR 0.64, 95{\%} confidence interval 0.61-0.67). A change over time in serum P level towards the 3.5 <. 5.5. mg/dL range from higher or lower ranges was associated with a decreased mortality, whereas only change in PTH level from <. 150. pg/mL to 150 <. 300. pg/mL range was associated with a lower risk of mortality. Upon discordant changes of PTH and P, i.e., decrease in one of the two measures while the other increased, no change in mortality risk was observed. Conclusion: In CKD-MBD management, patent survival is the greatest with controlling both serum P and PTH levels in balance. Tailoring an individualized treatment strategy in CKD-MBD may benefit patients. Further studies are needed.",
author = "Elani Streja and Wang, {Hsin Yi} and Lau, {Wei Ling} and Molnar, {Miklos Z.} and Kovesdy, {Csaba P.} and Kamyar Kalantar-Zadeh and Jongha Park",
year = "2014",
month = "4",
day = "1",
doi = "10.1016/j.bone.2014.01.016",
language = "English (US)",
volume = "61",
pages = "201--207",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients

AU - Streja, Elani

AU - Wang, Hsin Yi

AU - Lau, Wei Ling

AU - Molnar, Miklos Z.

AU - Kovesdy, Csaba P.

AU - Kalantar-Zadeh, Kamyar

AU - Park, Jongha

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Background: Mineral and bone disorder (MBD) is common and associated with mortality in patients with chronic kidney disease (CKD) Given that disarrays in serum phosphorus (P) and parathyroid hormone (PTH) levels and their changes over time are closely interrelated, modeling mortality-predictability of their combinations may help improve CKD patient management. Methods: A historical cohort study was undertaken to evaluate the joint effect of serum P and PTH levels on mortality in 107,299 chronic hemodialysis (HD) patients. Changes in serum P and PTH levels over 6. months, in particular discordant changes, were also modeled with mortality. Results: HD patients were 64. ±. 15 (mean. ±. SD). years old and included 45% women, 33% African-American, and 59% diabetic. Compared with serum P level ≥. 7.0. mg/dL and PTH level ≥. 600. pg/mL, adjusted hazard ratio (HR) tended to be lowest in patients with serum P level of 3.5 <. 5.5. mg/dL combined with PTH level of 150 <. 300. pg/mL (HR 0.64, 95% confidence interval 0.61-0.67). A change over time in serum P level towards the 3.5 <. 5.5. mg/dL range from higher or lower ranges was associated with a decreased mortality, whereas only change in PTH level from <. 150. pg/mL to 150 <. 300. pg/mL range was associated with a lower risk of mortality. Upon discordant changes of PTH and P, i.e., decrease in one of the two measures while the other increased, no change in mortality risk was observed. Conclusion: In CKD-MBD management, patent survival is the greatest with controlling both serum P and PTH levels in balance. Tailoring an individualized treatment strategy in CKD-MBD may benefit patients. Further studies are needed.

AB - Background: Mineral and bone disorder (MBD) is common and associated with mortality in patients with chronic kidney disease (CKD) Given that disarrays in serum phosphorus (P) and parathyroid hormone (PTH) levels and their changes over time are closely interrelated, modeling mortality-predictability of their combinations may help improve CKD patient management. Methods: A historical cohort study was undertaken to evaluate the joint effect of serum P and PTH levels on mortality in 107,299 chronic hemodialysis (HD) patients. Changes in serum P and PTH levels over 6. months, in particular discordant changes, were also modeled with mortality. Results: HD patients were 64. ±. 15 (mean. ±. SD). years old and included 45% women, 33% African-American, and 59% diabetic. Compared with serum P level ≥. 7.0. mg/dL and PTH level ≥. 600. pg/mL, adjusted hazard ratio (HR) tended to be lowest in patients with serum P level of 3.5 <. 5.5. mg/dL combined with PTH level of 150 <. 300. pg/mL (HR 0.64, 95% confidence interval 0.61-0.67). A change over time in serum P level towards the 3.5 <. 5.5. mg/dL range from higher or lower ranges was associated with a decreased mortality, whereas only change in PTH level from <. 150. pg/mL to 150 <. 300. pg/mL range was associated with a lower risk of mortality. Upon discordant changes of PTH and P, i.e., decrease in one of the two measures while the other increased, no change in mortality risk was observed. Conclusion: In CKD-MBD management, patent survival is the greatest with controlling both serum P and PTH levels in balance. Tailoring an individualized treatment strategy in CKD-MBD may benefit patients. Further studies are needed.

UR - http://www.scopus.com/inward/record.url?scp=84893763453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893763453&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2014.01.016

DO - 10.1016/j.bone.2014.01.016

M3 - Article

C2 - 24486956

AN - SCOPUS:84893763453

VL - 61

SP - 201

EP - 207

JO - Bone

JF - Bone

SN - 8756-3282

ER -